Role of aflibercept for macular edema following branch retinal vein occlusion: Comparison of clinical trials

Clinical Ophthalmology

Volumn 10, Issue , 2016, Pages 411-418

  Oellers, Patrick ^a,b   Grewal, Dilraj S ^a,b   Fekrat, Sharon ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Anti vascular endothelial growth factor; Bevacizumab; Branch retinal vein occlusion; BRVO; Cystoid macular edema; Dexamethasone implant; Grid pattern laser photocoagulation; Macular edema; Pegaptanib; Ranibizumab; Triamcinolone

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE;

BRAIN HEMORRHAGE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINAL THICKNESS; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; HEART INFARCTION; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; MACULAR EDEMA; NONFATAL MYOCARDIAL INFARCTION; RETINA DETACHMENT; REVIEW; VISUAL ACUITY;

EID: 84960368538     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S98853     Document Type: Review

References (43)

1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-141. discussion 41-3.
2. Rogers S, McIntosh RL, Cheung N, et al; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117:313.e1-319.e1
3. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126:513-518.
4. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1094.e5-1101.e5.
5. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984; 98:271-282.
6. Scott IU, Ip MS, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-1128.
7. Haller JA, Bandello F, Belfort R Jr., et al; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134.e3-1146.e3.
8. Wroblewski JJ, Wells JA 3rd, Adamis AP, et al; Central Retinal Vein Occlusion Study Group. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009;127:374-380.
9. Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina. 2011;31: 1856-1862.
10. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102.e1-1112.e1.
11. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122:538-544.
12. Bearelly S, Cooney MJ, Stinnett S, Fekrat S. Intravitreal triamcinolone for cystoid macular edema related to branch retinal vein occlusion. Ann Ophthalmol (Skokie). 2006;38:317-320.
13. Chen SD, Lochhead J, Patel CK, Frith P. Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol. 2004;88:154-155.
14. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;141:876-883.
15. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye (Lond). 2005;19:65-71.
16. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:782-783.
17. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315.
18. Haller JA, Bandello F, Belfort R Jr., et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453-2460.
19. Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105:412-416.
20. Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116:87-93.
21. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond). 2008;22: 42-48.
22. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 2011;56:281-299.
23. Ehlers JP, Fekrat S. Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion. Can J Ophthalmol. 2011;46: 88-89.
24. Ehlken C, Rennel ES, Michels D, et al. Levels of VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal vein occlusion. Am J Ophthalmol. 2011;152:298.e1-303.e1.
25. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
26. Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol. 2012;23:175-181.
27. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118: 1594-1602.
28. Sophie R, Hafiz G, Scott AW, et al. Long-term outcomes in ranibizumabtreated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol. 2013;156:693-705.
29. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119:802-809.
30. Campochiaro PA, Sophie R, Pearlman J, et al; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209-219.
31. Campochiaro PA, Wykoff CC, Singer M, et al. Monthly versus asneeded ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology. 2014;121:2432-2442.
32. Rush RB, Simunovic MP, Aragon AV 2nd, Ysasaga JE. Treat-andextend intravitreal bevacizumab for branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging Retina. 2014;45:212-216.
33. Narayanan R, Panchal B, Das T, et al; MARVEL Study Group. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol. 2015;99(7):954-959.
34. Martin DF, Maguire MG, Ying GS, et al; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
35. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193-1203.
36. Wroblewski JJ, Wells JA 3rd, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. Am J Ophthalmol. 2010;149:147-154.
37. Regnier SA, Larsen M, Bezlyak V, Allen F. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open. 2015;5: e007527.
38. Bakri SJ. Clinical trials: a need to better define the control group as current standard of care. Ophthalmology. 2015;122:443-444.
39. Hahn P, Fekrat S. Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place? Am J Ophthalmol. 2013; 155:415.e2-417.e2
40. Stone TW. ASRS preferences and trends membership survey. American Society of Retina Specialists (ASRS). 2015. Available from: https://www.asrs.org/content/documents/_2015-pat-survey-results.pdf. Accessed August 20, 2015.
41. Grunwald JE, Pistilli M, Ying GS, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122:809-816.
42. Tan MH, McAllister IL, Gillies ME, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol. 2014; 157:237.e-247.e.
43. Campochiaro PA, Hafiz G, Mir TA, et al. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE Trial. Ophthalmology. 2015; 122:1426-1437